[HTML][HTML] The development of COVID-19 treatment

Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

[HTML][HTML] IL-6/JAK/STAT3 signaling in breast cancer metastasis: biology and treatment

SG Manore, DL Doheny, GL Wong, HW Lo - Frontiers in oncology, 2022 - frontiersin.org
Breast cancer is the most commonly diagnosed cancer in women. Metastasis is the primary
cause of mortality for breast cancer patients. Multiple mechanisms underlie breast cancer …

[HTML][HTML] Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease

R Zeiser, N Polverelli, R Ram, SK Hashmi… - … England Journal of …, 2021 - Mass Medical Soc
Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic
stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in …

[HTML][HTML] A comprehensive overview of globally approved JAK inhibitors

AM Shawky, FA Almalki, AN Abdalla, AH Abdelazeem… - Pharmaceutics, 2022 - mdpi.com
Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

Current and future status of JAK inhibitors

DP McLornan, JE Pope, J Gotlib, CN Harrison - The lancet, 2021 - thelancet.com
An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …

Therapeutic options in VEXAS syndrome: insights from a retrospective series

E Bourbon, M Heiblig… - Blood, The Journal …, 2021 - ashpublications.org
Therapeutic options in VEXAS syndrome: insights from a retrospective series | Blood | American
Society of Hematology Skip to Main Content Advertisement Umbrella Alt Text Umbrella Alt Text …

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

DE Johnson, RA O'Keefe, JR Grandis - Nature reviews Clinical …, 2018 - nature.com
Abstract The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer,
and such hyperactivation is generally associated with a poor clinical prognosis. In the …

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

DM Schwartz, Y Kanno, A Villarino, M Ward… - Nature reviews Drug …, 2017 - nature.com
The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts
to target their associated signalling pathways. Janus kinases (JAKs) are essential signalling …

[HTML][HTML] Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer

Z Zeng, M Fu, Y Hu, Y Wei, X Wei, M Luo - Molecular Cancer, 2023 - Springer
Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset
of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their …

[HTML][HTML] Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for …

MM Li, M Datto, EJ Duncavage, S Kulkarni… - The Journal of molecular …, 2017 - Elsevier
Widespread clinical laboratory implementation of next-generation sequencing–based
cancer testing has highlighted the importance and potential benefits of standardizing the …